@adamfeuerstein Would love to have you do $INO article. While agree, co has been touting for a while, things have changed in last 3 yrs, no?— rockingrollingfun (@rocknrollingfun) August 6, 2013As far as I can tell, nothing has changed at Inovio Pharmaceuticals (INO - Get Report). The company is still flogging the synthetic vaccine and electroporation vaccine delivery technologies of 30 years ago. The other constant is Inovio's relentless self promotion. Two big changes over this time period: 1) Inovio's pipeline products fail or disappear, and 2) one group of disgruntled and money-losing retail investors is replaced by a new crowd of doe-eyed investors believing Inovio has turned the corner. Of course, this is never true. Rinse. Repeat.
Biotech Stock Mailbag: Sarepta, Inovio, FDA Calendar, Ken Luskin's Angry Vical Voice Mail
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.